Creat membership Creat membership
Sign in

Forgot password?

Confirm
  • Forgot password?
    Sign Up
  • Confirm
    Sign In
home > search

Now showing items 1 - 4 of 4

  • Układ antykoagulacyjny białka C w ostrych białaczkach

    Marzenna Galar   Jarosław Piszcz   Anna Szumowska   Łukasz Bołkun   Janusz Kłoczko (Prof. dr hab. med.)  

    | Figures/TablesFigures/Tables | ReferencesReferencesSTRESZCZENIERozwojowi ostrych białaczek już w momencie diagnozy towarzyszy subkliniczna aktywacja krzepnięcia. Zaburzenia hemostazy, wynikające m.in. z uszkodzenia śródbłonka i osłabionej funkcji syntetycznej wątroby, nie zawsze manifestują się jawną skazą krwotoczną lub chorobą zakrzepową. Wydolność mechanizmów kompensacyjnych na poziomie układu antykoagulacyjnego białka C - zapewnia równowagę hemostatyczną między czynnikami prozakrzepowymi i prokrwotocznymi. Badaniami objęto 20 chorych z nowo rozpoznanymi ostrymi białaczkami. W początkowym okresie rozwoju choroby obserwowano obniżenie stężeń antykoagulacyjnych białek syntezowanych w wątrobie (PC, PS) oraz wzrost sTM i znaczne obniżenie sEPCR - białkowych markerów uszkodzenia śródbłonka naczyń.
    Download Collect
  • Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma

    Agnieszka Oldziej   Lukasz Bolkun   Marzenna Galar   Joanna Kalita   Halina Ostrowska   Wioletta Romaniuk   Janusz Kloczko  

    Highlights • Proteasome concentration and its activity reflect the tumour burden in MM patients since patients in stage III had significantly higher levels compared to those in stage I. • The elevated proteasome concentrations found in advanced MM stages may be related to the growth of myeloma cells since the proteasome level correlate with IL-6 and β 2 M. • Higher proteasome ChT-L activity, unlike the concentration, was proved to be an indicator of a shorter progression free survival. Abstract The ubiquitin-proteasome pathway is implicated in the pathogenesis of many haematologic malignancies, including multiple myeloma. Under conditions of rapid cell turnover and growth rate, proteasomes are returned into circulation. The measurement of their levels or activity could offer a new approach to diagnosis, prognosis and monitoring of anticancer treatment in carcinoma patients. We analysed proteasome concentration and chymotrypsin-like (ChT-L) activity in the plasma of 64 patients with a newly diagnosed multiple myeloma and 30 healthy volunteers. The values were found to be significantly higher in the studied patients and advanced disease stages compared to the control group, and decreased significant after chemotherapy. Both proteasome concentration and ChT-L activity correlated with adverse prognostic factors, such as lactate dehydrogenase and β 2 -macroglobulin. We also showed that proteasome concentration positively correlates with IL-6 level, as opposed to proteasome ChT-L activity. Of note, higher proteasome ChT-L activity, unlike the concentration, was proved to be an indicator of a shorter progression free survival, constituting thereby an important prognostic marker.
    Download Collect
  • High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS

    Wioletta Romaniuk   Lukasz Bolkun   Joanna Kalita   Marzenna Galar   Malgorzata Bernatowicz   Halina Ostrowska   Janusz Kloczko  

    Proteasome inhibitors (PIs) such as bortezomib constitute an important part of the modern standard therapy for multiple myeloma (MM). In this study, we set out to assess whether proteasome concentration and chymotrypsin-like (ChT-L) activity could serve as potential biomarkers defining the likelihood of response to treatment with bortezomib, in order to identify patients who are more likely to respond to treatment with PI. We analysed proteasome concentration and ChT-L activity in the plasma of 78 patients with newly diagnosed MM during treatment with or without proteasome inhibitors. Values of all the studied parameters in the group of responders decreased sharply from the initial levels already after the third cycle of chemotherapy and remained significantly lower until the end of treatment. On the other hand, in the group of non-responders, there was an increase in the measured proteasome parameters already after the third cycle, and they remained high during the next cycles of therapy. We also showed that high baseline proteasome ChT-L activity values might prognosticate longer progression-free survival (PFS) in patients treated with PI. Our findings demonstrate that measuring plasma proteasome ChT-L activity can be used as a powerful biomarker for predicting clinical response to treatment and PFS in patients with newly diagnosed MM.
    Download Collect
  • The preliminary association study of ADIPOQ, RBP4, and BCMO1 variants with polycystic ovary syndrome and with biochemical characteristics in a cohort of Polish women

    Ewa Czeczuga-Semeniuk   Marzenna Galar   Katarzyna Jarząbek   Piotr Kozłowski   Nela A. Sarosiek   Sławomir Wołczyński  

    Abstract Purpose We aimed to elucidate the frequency of the SNPs in the ADIPOQ , RBP4 and BCMO1 genes in a population of Caucasian Polish women with polycystic ovary syndrome (PCOS), and to evaluate the possible associations between these variants and the susceptibility to PCOS. Additionally, the relationship of these polymorphisms to a clinical phenotype of this syndrome, and the concentrations of adipokines, were determined. Materials/methods Clinical and biochemical profiles, DNA isolation and genotyping, and adipokine assays were performed in 294 PCOS women and 78 controls. Results In a cohort of Polish women, for the genotype distribution and allele frequencies (minor allele frequency − MAF) proved that only the SNP rs1501299 in the gene ADIPOQ (P = 0.0010, OR = 0.41, 95% C.I.:0.24-0.70) and rs7501331 in the gene BCMO1 (P = 0.0106, OR = 0.24, 95% C.I.:0.21-0.71), are significantly associated (the latter marginally significant) with the decrease of the risk of the disease. Also for this SNPs there were significant differences in the genotypic frequencies in the study population. There was a link between rs12934922 of BCMO1 gen and serum concentration of RBP4 (P = 0.034) and adiponectin (P = 0.038) in the study group but not in the control group. The elevated mean serum concentration of cholesterol (P = 0.020) and LDL cholesterol (P = 0.005) was observed for GG rs1501299 genotype and triglycerides (P = 0.028) for TT rs2241766 genotype. Conclusions The results of the present study revealed that the genes variants RBP4 is not associated with PCO. It seems that rs1501299 of ADIPOQ gene influences the occurrence of PCO and lipids profile in those patients.
    Download Collect
1

Contact

If you have any feedback, Please follow the official account to submit feedback.

Turn on your phone and scan

Submit Feedback